Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuland Laboratories, a provider of active pharmaceutical ingredients (APIs), has reported $23m in revenues for the first quarter for FY 2012, an increase of 14.5%, compared to $20.3m for the same period last year.
Subscribe to our email newsletter
The increase in revenues primarily reflects gains in sales of the company’s products and services from its API, contract research and manufacturing and peptides synthesis businesses.
Neuland Labs CEO Sucheth Davuluri said a notable event during the first quarter was Neuland’s new commercial-scale peptide manufacturing service at a symposium for peptide experts from around the world.
"This expanded service, which provides customers rapid access to commercial quantities of affordable, high quality peptides," Davuluri said.